The impact would vary across different segments, with generics, biosimilars, and specialty drugs facing different challenges. Meanwhile, API and contract manufacturing firms may have some room to pass on the higher costs.
Your email address will not be published. Required fields are marked *
Save my name, email, and website in this browser for the next time I comment.
Leave a Comment